ID: ALA2321962

Max Phase: Preclinical

Molecular Formula: C17H10BrN3O4

Molecular Weight: 400.19

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C1Nc2c(Br)cccc2/C1=C1/Nc2cc(C(=O)O)ccc2/C1=N\O

Standard InChI:  InChI=1S/C17H10BrN3O4/c18-10-3-1-2-9-12(16(22)20-13(9)10)15-14(21-25)8-5-4-7(17(23)24)6-11(8)19-15/h1-6,19,25H,(H,20,22)(H,23,24)/b15-12-,21-14+

Standard InChI Key:  GGOSCGOWOVGYLY-HQMCVCOQSA-N

Associated Targets(Human)

Dual-specificity tyrosine-phosphorylation regulated kinase 2 2095 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cyclin-dependent kinase 5 3021 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Arachidonate 5-lipoxygenase 6568 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

KCL-22 265 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Dual specificity tyrosine-phosphorylation-regulated kinase 1A 1629 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Casein kinase I isoform alpha 80 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Glycogen synthase kinase 3 beta 55 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 400.19Molecular Weight (Monoisotopic): 398.9855AlogP: 3.11#Rotatable Bonds: 1
Polar Surface Area: 111.02Molecular Species: ACIDHBA: 5HBD: 4
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 4.53CX Basic pKa: CX LogP: 2.22CX LogD: -1.07
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.33Np Likeness Score: 0.05

References

1. Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, Magiatis P, Ferandin Y, Durieu E, Lozach O, Cappel D, Soundararajan M, Filippakopoulos P, Sherman W, Knapp S, Meijer L, Mikros E, Skaltsounis AL..  (2013)  Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.,  (1): [PMID:23336033] [10.1021/ml300207a]
2. Pergola C, Gaboriaud-Kolar N, Jestädt N, König S, Kritsanida M, Schaible AM, Li H, Garscha U, Weinigel C, Barz D, Albring KF, Huber O, Skaltsounis AL, Werz O..  (2014)  Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.,  57  (9): [PMID:24697244] [10.1021/jm401740w]
3. Gaboriaud-Kolar N, Myrianthopoulos V, Vougogiannopoulou K, Gerolymatos P, Horne DA, Jove R, Mikros E, Nam S, Skaltsounis AL..  (2016)  Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.,  79  (10): [PMID:27726390] [10.1021/acs.jnatprod.6b00285]

Source